Neoprobe Corporation to Change Company Name to Navidea Biopharmaceuticals
08 12월 2011 - 10:30PM
Business Wire
Neoprobe Corporation (NYSE Amex: NEOP), today announced that it
will change its name to Navidea Biopharmaceuticals, Inc. The
Company is also scheduled to begin trading under a new ticker
symbol (NAVB) on the NYSE Amex exchange at market open on January
5, 2012.
In connection with the sale of the neoprobe® GDS medical device
business and related brand name (Neoprobe) to Devicor Medical
Products in August 2011, the Company commenced a corporate
re-branding initiative reflecting its business pursuits in the
precision diagnostics space. Navidea was chosen as the new name to
reflect the Company’s dedication to “NAVigating IDEAs” that
translate cutting edge innovation and precision diagnostics
technology into novel products to advance patient care.
"Our new corporate identity signifies the Company's
transformation into a biopharmaceutical company focused on
development and commercialization of precision radiopharmaceutical
diagnostics for cancer and other significant disease areas,” said
Dr. Mark Pykett, Neoprobe President and CEO. “We plan to reveal a
more complete view of the Navidea brand and an updated website in
January in connection with the legal change in our corporate name
and as we begin trading under our new ticker symbol, NAVB. In the
meantime, we wanted to provide advance notice of the change. As
Navidea, we will continue to focus our efforts on the approval and
commercialization of Lymphoseek® and on our development efforts
surrounding RIGScan™. In addition, we plan to actively move forward
with other pipeline development opportunities, including the
in-licensing or acquisition of other promising agents.”
About Neoprobe (Navidea Biopharmaceuticals)
Neoprobe Corporation (NYSE Amex: NEOP) is a biopharmaceutical
company focused on the development and commercialization of
precision diagnostics and radiopharmaceutical agents. Neoprobe is
actively developing two radiopharmaceutical agent platforms –
Lymphoseek® and RIGScanTM CR – to help identify the sites and
pathways of undetected disease and enable better diagnostic
accuracy, clinical decision-making and ultimately patient care.
Neoprobe’s strategy is to deliver superior growth and shareholder
return by bringing to market novel radiopharmaceutical agents and
advancing the Company’s pipeline through selective acquisitions,
global partnering and commercialization efforts. For more
information, please visit www.neoprobe.com.
The Private Securities Litigation Reform Act of
1995 (the Act) provides a safe harbor for forward-looking
statements made by or on behalf of the Company. Statements in this
news release, which relate to other than strictly historical facts,
such as statements about the Company’s plans and strategies,
expectations for future financial performance, new and existing
products and technologies, anticipated clinical and regulatory
pathways, and markets for the Company’s products are
forward-looking statements within the meaning of the Act. The words
“believe,” “expect,” “anticipate,” “estimate,” “project,” and
similar expressions identify forward-looking statements that speak
only as of the date hereof. Investors are cautioned that such
statements involve risks and uncertainties that could cause actual
results to differ materially from historical or anticipated results
due to many factors including, but not limited to, the Company’s
continuing operating losses, uncertainty of market acceptance of
its products, reliance on third party manufacturers, accumulated
deficit, future capital needs, uncertainty of capital funding,
dependence on limited product line and distribution channels,
competition, limited marketing and manufacturing experience, risks
of development of new products, regulatory risks and other risks
detailed in the Company’s most recent Annual Report on Form 10-K
and other Securities and Exchange Commission filings. The Company
undertakes no obligation to publicly update or revise any
forward-looking statements.
Neoprobe Corp. Common Stock (AMEX:NEOP)
과거 데이터 주식 차트
부터 5월(5) 2024 으로 6월(6) 2024
Neoprobe Corp. Common Stock (AMEX:NEOP)
과거 데이터 주식 차트
부터 6월(6) 2023 으로 6월(6) 2024